New PrEP Study: SeroPrEPPosted August 31, 2023
Colleagues at UCSF are conducting a study called SeroPrEP to characterize new HIV infections among persons using long-acting injectable cabotegravir (CAB-LA) or oral PrEP.
SeroPrEP is an observational (non-interventional) study that aims to evaluate causes of HIV acquisition on CAB-LA or oral PrEP via sensitive assays for ARV resistance, drug levels/pharmacokinetics (PK), and diagnostics; and assess subsequent HIV treatment outcomes on ART. The study is funded by the National Institutes of Health.
Participant eligibility criteria include:
- One or more HIV tests suggesting that HIV-1 infection has occurred (e.g. Ag/Ab, RNA)
- Use/receipt of CAB-LA in the past 18 months or oral PrEP in the past 3 months
- Age >= 18 years
The study involves:
- A brief online participant survey and e-consent
- A brief online clinician survey
- Collection of blood, urine, and small scalp hair samples
- A behavioral questionnaire
- Follow-up for up to 12 months in the study to assess ART outcomes
SeroPrEP enrolls participants from all 50 U.S. states and Puerto Rico. Patients who enroll in the study receive a $50 gift card for each study visit.
Enrollment information can be found on our study website. See below for a Study Flyer, Study Slide and Dear Provider letter – please circulate these to your colleagues who may have patients eligible for the study.
Click below to download the Sero PrEP
Click below to download the SeroPrEP Dear Doctor Letter:
Click below to download the SeroPrEP Overview Slide:
Please let the SeroPrEP study team know if it would be possible to include their study information in your newsletters/network communications, or to include their study slide in trainings related to long-acting HIV prevention, PrEP, or HIV testing.
The SeroPrEP team
Catherine Koss, MD; Urvi Parikh, PhD;
Monica Gandhi, MD, MPH; Lisa Georgetti Gomez, MSPH
Subscribe to receive new resources in your inboxSubscribe